The Vesicular Monoamine Transporter 2 (VMAT2) is responsible for transporting monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine from the cytoplasm into synaptic vesicles. This VMAT2 mediated transport governs essential brain pathways, controlling functions like movement, sleep, and mood regulation. Dysfunction in these pathways is implicated in various psychiatric or neurodegenerative disorders, making VMAT2 a promising drug target. This study utilized a structure-based approach to identify novel VMAT2 inhibitor candidates. Initially, molecular docking identified several promising compounds when compared to standard inhibitors. Three novel compounds (S31, S42, and S48) that bind to VMAT2′s active site were further evaluated using molecular dynamics (MD) simulations, and their binding-free energies were calculated. Among these, S42 formed the most stable complex with VMAT2, exhibiting the lowest binding free energy and interacting with key residues such as Val-232 and Leu-37, which may confer selectivity. Additionally, S42 demonstrated superior binding strength in pulling simulations relative to other candidates and standard molecules. Umbrella sampling simulations further supported S42 as a strong candidate for VMAT2 inhibition. In conclusion, S42 warrants further investigation to fully explore its therapeutic potential.
Read full abstract